Biocon, the biotech company, reported a 57% decline in its consolidated net profit for the fourth quarter ending March 2024, reaching Rs 136 crore compared to Rs 313 crore in the same period last year. Despite a marginal increase in total revenue to Rs 3,966 crore from Rs 3,929 crore in the year-ago period, the company’s total expenses surged to Rs 3,635 crore. For the full fiscal year ending March 31, 2024, Biocon’s consolidated net profit rose significantly to Rs 1,022 crore from Rs 463 crore in the previous year. Total revenue also saw a notable increase to Rs 15,621 crore from Rs 11,550 crore in the 2022-23 fiscal year.